Genetic Variation of the GLUT10 Glucose Transporter (SLC2A10) and Relationships to Type 2 Diabetes and Intermediary Traits
- Gitte Andersen1,
- Christian Schack Rose1,
- Yasmin Hassan Hamid1,
- Thomas Drivsholm2,
- Knut Borch-Johnsen1,
- Torben Hansen1 and
- Oluf Pedersen13
- 1Steno Diabetes Center and Hagedorn Research Institute, Gentofte, Denmark
- 2Centre of Preventive Medicine, Glostrup University Hospital, Glostrup, Denmark
- 3Faculty of Health Science, University of Aarhus, Aarhus, Denmark
- Address correspondence and reprint requests to Gitte Andersen, Steno Diabetes Center, Niels Steensens Vej 2, NSH2.16, DK-2820 Gentofte, Denmark. E-mail: gtta{at}steno.dk
Abstract
The SLC2A10 gene encodes the GLUT10 facilitative glucose transporter, which is expressed in high amounts in liver and pancreas. The gene is mapped to chromosome 20q12-q13.1, a region that has been shown to be linked to type 2 diabetes. The gene was examined in 61 Danish type 2 diabetic patients, and a total of six variants (−27C→T, Ala206Thr, Ala272Ala, IVS2 + 10G→A, IVS4 + 18T→G, and IVS4 + 26G→A) were identified and investigated in an association study, which included 503 type 2 diabetic patients and 510 glucose-tolerant control subjects. None of the variants were associated with type 2 diabetes. Interestingly, carriers of the codon 206 Thr allele had 18% lower fasting serum insulin levels (P = 0.002) and 20% lower insulinogenic index (P = 0.03) than homozygous carriers of the Ala allele. These results suggest that variation in the coding region of SLC2A10 does not contribute substantially to the pathogenesis of type 2 diabetes in the examined study population. However, the codon 206 polymorphism may be related to the interindividual variation in fasting and oral glucose-induced serum insulin levels.
- AUC, area under the curve
- HNF, hepatic nuclear factor
- OGTT, oral glucose tolerance test
- PTP-1B, protein tyrosine phosphatase-1B
- RG, restriction-site generating
Footnotes
-
K.B.-J. is the Medical Director of the Steno Diabetes Center, a hospital owned by Novo Nordisk but providing service for the national health care system in Denmark; holds stock in Novo Nordisk; and has received grant support from Novo Nordisk.
-
- Accepted May 22, 2003.
- Received December 20, 2002.
- DIABETES














